Evidence map›Paper›PMID 36839811›Full record

ArticlePharmaceutics2023

Boosting the In Vivo Transdermal Bioavailability of Asenapine Maleate Using Novel Lavender Oil-Based Lipid Nanocapsules for Management of Schizophrenia.

Fatma Sa'eed El-Tokhy, Mona M A Abdel-Mottaleb, Sherif S Abdel Mageed, Abdulla M A Mahmoud, Elsayed A El-Ghany, Ahmed S Geneidi

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. A Comprehensive Review on Anxiolytic Effect ofFood science & nutrition · 2025
    Review
  3. Review
  4. Article
  5. Mechanistic Wound Healing ofInternational journal of molecular sciences · 2025
    Article
  6. Review
  7. Article
  8. Medicinal Anti-Inflammatory Patch Loaded with Lavender Essential Oil.International journal of molecular sciences · 2024
    Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Fatma Sa'eed El-TokhyDepartment of Pharmaceutics, Faculty of Pharmacy, Badr University in Cairo (BUC), Badr City 11829, Egypt.ORCID 0000-0002-3942-8034
Mona M A Abdel-MottalebDepartment of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo 11566, Egypt.ORCID 0000-0002-4017-1248
Sherif S Abdel MageedPharmacology and Toxicology Department, Faculty of Pharmacy, Badr University in Cairo, Badr City 11829, Egypt.ORCID 0000-0003-0702-5035
Abdulla M A MahmoudPharmacology and Toxicology Department, Faculty of Pharmacy, Badr University in Cairo, Badr City 11829, Egypt.ORCID 0000-0002-5930-4266
Elsayed A El-GhanyDepartment of Pharmaceutics, Faculty of Pharmacy, Badr University in Cairo (BUC), Badr City 11829, Egypt.
Ahmed S GeneidiDepartment of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo 11566, Egypt.
Badr University in Cairo · EGAin Shams University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lipid nanocapsules (LNCs) are promising for transdermal drug delivery due to their higher permeability-enhancing effects compared to polymeric nanoparticles. Lavender oil is an essential oil consisting of several terpenes (primarily linalool and linalyl acetate) known for their profound permeation-enhancing action. In the present work, we successfully encapsulated asenapine maleate (a second-generation antipsychotic that is highly metabolized by the liver, reducing its oral bioavailability) into biocompatible LNCs for transdermal application using a novel oily phase, i.e., lavender oil (LO-LNCs). A comparative study was conducted to determine the effects of different oily phases (i.e., Miglyol

Indexed as

asenapine maleatelavender oillipid nanocapsulesmedium-chain triglyceridestransdermal drug delivery

Identifiers

PMID36839811
PMCPMC9963881
OpenAlexW4319027417

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.